In a report released today, Asthika Goonewardene from Truist Financial maintained a Buy rating on Exelixis (EXEL – Research Report), with a price target of $42.00. The company’s shares closed ...

Exelixis (EXEL), which belongs to the Zacks Medical - Biomedical and Genetics industry, could be a great candidate to consider. When looking at the last two reports, this drug developer has ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Many investors also have a go-to methodology ...